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Background: The differentiation of constrictive pericarditis (CP) from restrictive cardiomy-
opathy (RCM) may be clinically difficult and may require multiple investigations. Even
though brain natriuretic peptide (BNP) is shown to be higher in patients with RCM as
compared to CP, the clinical utility is not fully established especially in Indian patients
known to have advanced CP and myocardial involvement.
Methods and results: We measured NT-pro-BNP levels in 49 patients suspected of having
either CP or RCM, diagnosed on the basis of echocardiography, computed tomography,
magnetic resonance imaging, endomyocardial biopsy and cardiac catheterization data as
needed. Twenty nine patients (Mean age e 26 yrs, 24 males) had CP and 20 patients (Mean
age e 39 yrs, 14 males) had RCM. The median plasma NT-pro-BNP levels were significantly
higher in RCM as compared to CP [1775 (208e7500) pg/ml vs 124 (68e718) pg/ml, respec-
tively; p ¼ 0.001]. A cut off value of 459 pg/ml had sensitivity, specificity and overall ac-
curacy of 90%, 86% and 88% respectively, for differentiating CP from RCM.
Conclusions: The NT-pro-BNP levels are significantly elevated in RCM as compared to CP.
Copyright © 2015, Cardiological Society of India. All rights reserved.1. Introduction
Differentiation between constrictive pericarditis (CP) and
restrictive cardiomyopathy (RCM) has always been a difficult
task for the clinicians. The differentiation is crucial as CP is
curable surgically whereas RCM needs conservativeiology, Suite # 32, 7th Flo
1 11 26588663, þ91 11 26
. Ramakrishnan).
ciety of India. All rightsmanagement with poor prognosis. Patients need to undergo
various investigations like echocardiography including tissue
Doppler, computed tomography and magnetic resonance
imaging, one after the other and may require cardiac cathe-
terization many a times to differentiate between the two
conditions. An individual test is often unable to differentiateor, C. N. Center, All India Institute of Medical Sciences, New Delhi
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by cardiac catheterization may miss up to one fourth of the
cases of CP.1
Brain natriuretic peptide (BNP) is secreted from ventricular
myocyte in response to ventricular overload.2,3 Its secretion is
influenced by various hemodynamic factors.4 BNP levels are
increased in various conditions like cardiac diseases (heart
failure, acute myocardial infarction, hypertension with left
ventricular hypertrophy), pulmonary diseases (chronic
obstructive pulmonary diseases, pulmonary embolism),
endocrine diseases, renal diseases and cirrhosis of liver. It is
secreted as a pre-prohormone that splits into BNP and func-
tionally inactive NT-pro-BNP. Half life of BNP is much lesser
than NT-pro-BNP hence concentration of BNP are lesser.5 The
action of this peptide, like those of atrial natriuretic peptide,
includes natriuresis, vasodilatation, inhibition of the renin-
angiotensin-aldosterone axis, and inhibition of sympathetic
nerve activity.6
In CP, there is no stretch on themyocardium because of the
constrictive effect of the diseased pericardium, but in RCM the
restrictive effect is in ventricular myocardium which pro-
duces significant atrial stretch. Due to this inherent difference
in the physiology of these two conditions, the levels of BNP/
NT-pro-BNP are found to be lower in CP in contrast to RCM.7
Indian patients with CP often present late with advanced
myocardial involvement and have tubercular etiology most of
the time.8 Hence, we conducted this study to evaluate the
utility of NT-pro-BNP levels as a differentiating marker be-
tween Indian patients with RCM and predominantly tuber-
cular CP.2. Methods
All patients with a diagnosis of CP or RCM on the basis of
clinical examination, echocardiography, computed tomogra-
phy (CT), magnetic resonance imaging (MRI) and hemody-
namic assessment were included in the study after an
informed consent. CP due to radiation pericarditis and post
cardiac transplant was excluded from the study. RCM due to
various causes like idiopathic, endomyocardial fibrosis (EMF),
amyloidosis, hemochromatosis and sarcoidosis were included
in the study. Patients with features suggestive of both RCM
and CP, e.g. radiation associated myopericardial involvement
were excluded from the study as the basic aim of the study
was to focus on the discriminatory value of NT-pro BNP for
differentiating between RCM and CP. RCM patients with end
stage disease and on transplant list were also excluded
because multiple comorbidities associated with very
advanced disease may confound the overall result of the
study. End stage patients were defined as NYHA class IV pa-
tients who required hospitalization, intravenous medications
and a median life expectancy of about 6 months. The study
was approved by Institute's Ethics committee.
All patients suspected to have CP or RCM underwent
complete clinical and echocardiographic evaluation. A 6-min
walk test was done as per standard protocols. Echocardio-
gram was performed by a cardiologist with vast experience in
this field. A comprehensive echocardiogram which included
respiratory variation in mitral/tricuspid inflow velocities,atrial enlargement, septal thickness, mitral regurgitation
(MR), tricuspid regurgitation (TR), TR gradient, pericardial
thickness, pericardial calcification, myocardial architecture
and tissue doppler was performed. Patients with primary
diagnosis of CP were subjected to cardiac CT, while those with
primary diagnosis as RCM were subjected to MRI/cardiac
catheterization and endomyocardial biopsy for further
confirmation and diagnosing the etiology of RCM. In case of
diagnostic dilemma, usually a CT was done followed by MRI/
cardiac catheterization if diagnosis is still elusive. CP diag-
nosis was finally confirmed on surgery for patients who un-
derwent pericardiectomy.
All the patients with confirmed diagnosis of either condi-
tion on the basis of clinical evaluation, echocardiography, CT
or MRI and hemodynamic assessment were enrolled in the
study. The blood sample for NT-pro-BNP was obtained in the
morning after at least 30-min rest. NT-pro-BNP measurement
was done for all the patients using quantitative assay for NT-
pro-BNP by Roche diagnostics, Basel, Switzerland.3. Statistical analysis
Statistical analysis was performed using STATA 11.0 (College
Station, Texas, USA) statistical software. Results are presented
as mean (SD) when parametric tests were used, and median
(IQR) when non-parametric tests were used. Student's t-test
was done to compare the means of continuous variables.
Two-sample Mann Whitney test was used to compare non-
parametric variables. A p value of <0.05 was taken as signifi-
cant. Nonparametric estimation of receiver operating char-
acteristics curve was used to derive cut off values for NT-pro-
BNP levels.4. Results
We studied 49 patients with confirmed diagnosis of either
RCM or CP based on various tests. No patient was excluded
due to suspected radiation CP. Two patients with RCM were
excluded as they were of end stage disease. All these patients
were on a stable dose of standard therapy including diuretics,
ACE inhibitors and beta blockers. All patients had normal
renal functions. Table 1 summarizes the characteristics of the
two groups of patients. Patients with CP were younger, had
relatively lower hemoglobin values and higher ESR as
compared to RCM. Various other parameters like duration of
disease, NYHA class, extent of hepatomegaly, 6-min walk test
and left ventricular (LV) function were not statistically
different between the two groups. None of the patients in the
CP group had atrial or ventricular enlargement on echocardi-
ography. Similarly, none of the patients in the RCM group had
pericardial thickening, calcification or effusion. Majority of
patients [24 (82%)] in the CP group had significant respiratory
variation in mitral/tricuspid inflow velocities while none in
the RCM group had this finding. A mitral annular early dia-
stolic velocity of >8 cm/s was seen in all patients with CP and
in 3 (15%) with RCM. All patients with CP were of tubercular
etiology and had completed or were receiving antitubercular
treatment (ATT). In the RCM group 2 had cardiac amyloidosis,
Table 1 e Baseline characteristics and comparison of two
groups.
CP RCM P value
No of patients 29 20
Age (yrs) 25.7 ± 13.2 39.2 ± 20 0.007
Gender (male) 24 (83%) 14 (70%) NS
Duration of disease
(months)*
12 (2e120) 24 (1e60) NS
NYHA class 2.65 ± 0.63 2.7 ± 0.73 NS
Hepatomegaly (cms) 3.3 ± 1.0 2.8 ± 0.97 NS
6 min walk test (meters) 372 ± 60 363 ± 29 NS
Hemoglobin (gm/dl) 11.3 ± 1.1 12.4 ± 2.1 0.05
ESR 27.7 ± 9.9 15.4 ± 3.7 0.0007
NT-pro-BNP (pg/ml)* 124 (68e718) 1775 (208e7500) 0.0001
LV function (%) 56 ± 4.7 58 ± 6.2 NS
Values displayed as mean ± standard deviation except for * values
which are expressed as median (IQR).
CP ¼ constrictive pericarditis, RCM ¼ restrictive cardiomyopathy,
NYHA ¼ New York Heart Association, ESR ¼ Erythrocyte Sedi-
mentation Rate, LV ¼ left ventricular.
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cardial fibrosis (EMF) and the rest were idiopathic RCM.
Echocardiography was diagnostic in all patients except in 2
patients, out of whom one turned out to be CP after cardiac CT
while in other CT was noncontributory and a cardiac MR
clinched the diagnosis of RCM. In the CP group two patients
recoveredwith ATTwithout signs of CP in the follow up period
and one was managed conservatively due to improvement in
symptoms after ATT. Rest of the 26 patients underwent peri-
cardiectomy and the diagnosis was confirmed intra-
operatively and in biopsy specimens. NT-pro-BNP levels were
significantly higher in the patients with RCM as compared to
CP with a median (IQR) value of 1775 (208e7500) pg/ml vs 124
(68e718) pg/ml, respectively (p ¼ 0.001). A cut off value of
459 pg/ml had sensitivity, specificity and overall accuracy of
90%, 86% and 88% respectively, for differentiating CP from
RCM. In patients whom echocardiography was inconclusive,
NT-pro-BNP was able to differentiate between the two with
cut off value of 459 pg/ml. The sensitivity and specificity of
various cut off values of NT-pro-BNP in differentiating the two
conditions are summarized in Table 2.5. Discussion
Differentiation of CP from RCM is difficult and at times the
diagnosis is only made in operation theater or on autopsy.
Given the limitations of existing diagnostic modalities for
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459 90 86 88
740 85 100 94pro-BNP in this patient population as an ancillary diagnostic
modality. The plasma level of BNP is elevated in patients with
congestive heart failure and increases in proportion to the
degree of left ventricular dysfunction and the severity of
symptoms of heart failure.3,9 BNP and its amino-terminal
portion (NT-pro-BNP), appears to be a powerful neurohor-
monal predictor of LV function and prognosis in various
conditions including myocardial infarction and acute coro-
nary syndrome.5,10,11 As NT-pro-BNP is relatively stable form
than BNP, its levels are 1e3 times more than the corre-
sponding BNP levels in the same patient.12 The age differences
in NT-pro-BNP is also important but in various studies, pop-
ulation <50 yrs has been clubbed in one group and our study
population included mainly patients under 50 yrs of age.
Although, someminor changes in BNP levels may occur it will
not change the utility of NT-pro-BNP as seen in this study.13,14
It has been hypothesized by Leya et al that NT-pro-BNP
level should not be elevated in CP.7 On the contrary, RCM
will have elevatedNT-pro-BNP levels. An earlier study showed
that plasma levels of BNP and BNP receptors are elevated in
patients with RCM.15 Although atrial natriuretic peptide is
known to bemodestly increased in patients with CP compared
to congestive heart failure from other etiology, few studies
had evaluated direct comparison between CP versus RCM.16
The difference in natriuretic peptide levels in CP and RCM,
despite having similar degree of congestion and elevated
ventricular diastolic pressures is due to the basic difference in
the BNP kinetics in constrictive versus restrictive physiology.
In CP, thickened and constricting pericardium effectively
counter-balances the intracardiac distending pressure and
thus negating the stimulus for BNP release. In RCM the
stretch/distending stimulus is unchecked resulting in higher
BNP release.7 Sengupta et al compared the utility of mean
early diastolic mitral annular tissue Doppler imaging and BNP
in differentiating CP and RCM. They found tissue doppler
imaging to have more discriminative value in differentiating
the two conditions with little overlap (area under the curve
0.97 vs 0.76, respectively; p ¼ 0.01), while larger overlap be-
tween the twowas seenwith BNP values less than 400 pg/ml A
mean annular velocity of 5 cm/s correctly distinguished CP
from RCMP, even when there was a large overlap of BNP be-
tween the 2 groups. In this study the subgroup of patientswith
idiopathic CP had lower BNP value and thus still maintaining
the discriminatory value for RCM.17 The utility of BNP get
blunted in the presence of renal failure as shown by Reddy
et al in a subgroup of patients with RCM and CP with renal
failure. In patients with GFR <90 ml/min the discriminatory
value of BNP became insignificant. Elevation in BNP due to
renal failure was the reason for this effect. The patients in this
study were older than that of our study and most of the CP
were post thoracic surgery.18 In our study none of the patient
had renal dysfunction, younger in age and thus discrimina-
tory value of NT-pro-BNP was better in our study.
In study by Babuin et al 11 patients each of idiopathic CP,
secondary CP and RCM were compared. Median BNP was 80
(44e193) pg/ml for idiopathic CP, 278 (118e526) pg/ml for
secondary CP, and 499 (361e606) pg/ml for RCM. Secondary CP
patients were either post operative or post radiation therapy
and had higher BNP levels.19 In our study, all patients were of
tubercular CP and is in sync with Babuin's study regarding the
Table 3 e Comparison of various studies of BNP/NT-pro-BNP in CP and RCM.
Study
(Year)
Diagnosis No of pts Pts with idiopathic CP Age (yrs) BNP/NT-pro-BNPa levels (pg/ml)
Leya FS
2005
CP 6 e 64.2 ± 10.2 128.0 ± 52.7
RCM 5 54.2 ± 17.7 825.8 ± 172.2
Babuin L
2006
Idiopathic CP 11 51.7 ± 11.1 80 (44e193)y
Secondary CP 11 62.0 ± 10.3 278 (118e526)y
RCM 11 58.8 ± 10.2 499 (361e606)y
Reddy PR
2007
CP (GFR <90 ml/min) 9 2 65.9 ± 17.1 434 ± 307
CP (GFR>(90 ml/min) 8 2 53.8 ± 11.6 124 ± 97.5
RCM 5 e 681 ± 400
Sengupta PP
2008
CP 16 7 61.8 ± 13 231 ± 104
RCM 15 60.5 ± 9 595 ± 499
Mady C
2008
CP 16 e 32 ± 16 568a
EMF 26 49 ± 7 633a
Control 40 36 ± 10 28a
Kapoor PM
2010
CP 24 24 32 (15e55)y 513.71 ± 147.21
Parakh N
2014
CP 29 29 25.7 ± 13.2 124 (68e718)y,a
RCM 20 39.2 ± 20 1775 (208e7500)y,a
CP, constrictive pericarditis; RCM, restrictive cardiomyopathy; All values are in mean ± SD except y values are expressed as median (IQR).
a Studies measuring NT-pro-BNP.
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and RCM.
Kapoor et al measured BNP levels in 24 tubercular CP pa-
tients before and after pericardiectomy and compared it with
various parameters of ventricular functions. They found a
good correlation in BNP levels and diastolic dysfunction in
these patients while correlation with systolic function was
poor. Patients in this study had very high initial value of BNP
(mean 514 pg/ml) as these patients were much sicker, had
advanced NYHA class (NYHA III 75%, NYHA IV 25%) and
almost half of them had renal dysfunction.8 All these studies
measured BNP levels, while Mady et al studied NT-pro-BNP
levels in various cardiomyopathies like hypertrophic cardio-
myopathy, chagasic cardiomyopathy, EMF, CP and pericardialFig. 1 e Algorithm for the differentiation of CP and RCM. CP e con
e computerized tomography; MR e magnetic resonance imagineffusion (Table 3). Mean NT-pro-BNP levels were 633 ng/ml
and 588 ng/ml in EMF and CP respectively and this difference
was not significant. Reasons for this finding could be because
of patients in CP group were NYHA class I/II while most of the
patients (80%) in EMF group were class III/IV. All patients in
restrictive group were of EMF a finding much different from
other studies where idiopathic RCM is predominant
diagnosis.20
In our study echocardiography by an expert cardiologist
was able to differentiate between RCM and CP with accuracy
of 95%. In two patients where echocardiography was incon-
clusive, NT-pro-BNP cut off value of 459 pg/ml was able to
differentiate between the two. In centers/operators with
lesser expertise in echocardiography, NT-pro-BNP may havestrictive pericarditis; RCM e restrictive cardiomyopathy; CT
g.
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CP and generalizability of these findings to other groups need
further studies. We found in our study that both the groups
had similar degree of heart failure as judged by NYHA class
and hepatomegaly. Despite that level of NT-pro-BNP were
only mildly elevated or normal in patients with CP. Our study
confirms the earlier finding of possible use of BNP/NT-pro-BNP
as an ancillary tool in differentiating CP from RCM. A possible
algorithm is proposed in Fig. 1.6. Limitations
Our study is also limited by small sample size, although the
size is sufficiently large to conclude that the levels of NT-pro-
BNP are higher in restrictive cardiomyopathy as compared to
constrictive pericarditis.7. Conclusions
We conclude from this study that NT-pro-BNP is a useful
marker to differentiate restrictive cardiomyopathy from
constrictive pericarditis and can be used in diagnostic proto-
col in cases where the differentiation between the two con-
ditions is difficult by other tests.Funding
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